MedTrace Logo

Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.

NCT06344715 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2024-04-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of SL-T10 and GX-I7 or SL-T10, GX-I7 and pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).

Conditions

  • Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions

BIOLOGICAL

SL-T10

A therapeutic DNA vaccine containing three prostate cancer-specific antigen genes and genetic adjuvants

BIOLOGICAL

GX-I7

A T-cell growth factor

BIOLOGICAL

Pembrolizumab

An immune check point inhibitor

Sponsors & Collaborators

  • SL VAXiGEN

    lead INDUSTRY

Principal Investigators

  • Cheol Kwak, MD, phD · Seoul National University Hospital

  • Chang Wook Jeong, MD, phD · Seoul National University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-17
Primary Completion
2024-10-31
Completion
2024-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06344715 on ClinicalTrials.gov